OptimizeRx (OPRX) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Company overview and business model
Operates as a healthcare technology company connecting life sciences brands with patients and healthcare providers through AI-driven digital marketing and communication solutions.
Expanded capabilities via acquisition of Medicx Health, enabling privacy-centric direct-to-consumer marketing using de-identified claims data and micro-neighborhood targeting.
Offers omnichannel marketing solutions leveraging machine learning to optimize audience targeting for both healthcare professionals and patients.
Connects over two million U.S. healthcare providers and millions of patients through a proprietary digital platform.
Financial performance and metrics
Classified as a "smaller reporting company" under SEC rules, allowing for reduced disclosure obligations and streamlined financial reporting.
Use of proceeds and capital allocation
Net proceeds from securities sales are intended primarily for working capital and general corporate purposes, with specific uses to be detailed in future prospectus supplements.
Latest events from OptimizeRx
- Record FY25 results, robust cash flow, and a $10M buyback set a cautious FY26 outlook.OPRX
Q4 20255 Mar 2026 - Q3 2025 saw 22% revenue growth, margin expansion, and raised guidance for 2025–2026.OPRX
Q3 20253 Feb 2026 - Q2 revenue up 36% to $18.8M, gross margin 62.2%, full-year guidance reaffirmed.OPRX
Q2 20242 Feb 2026 - Q3 revenue up 30% to $21.3M; 2024 guidance $88–92M, with strong margin and client growth.OPRX
Q3 202414 Jan 2026 - Q4 and FY 2024 revenue and margin gains set up strong 2025 guidance and subscription growth.OPRX
Q4 202426 Dec 2025 - Proxy seeks approval for board nominees, executive pay, and auditor, highlighting governance and ESG.OPRX
Proxy Filing1 Dec 2025 - Stockholder plans to nominate two board candidates; board's recommendation pending proxy filing.OPRX
Proxy Filing1 Dec 2025 - Q1 2025 revenue up 11%, net loss narrowed, and guidance raised on strong contracted growth.OPRX
Q1 202526 Nov 2025 - Q2 2025 revenue up 55%, profitability restored, and guidance raised on strong digital growth.OPRX
Q2 202523 Nov 2025